Galmed Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Galmed Pharmaceuticals has been growing earnings at an average annual rate of 21.5%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
21.5%
Earnings growth rate
29.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -34.3% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
May 16
Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 06Galmed GAAP EPS of -$0.15 beats by $0.09
Aug 04Companies Like Galmed Pharmaceuticals (NASDAQ:GLMD) Could Be Quite Risky
May 03Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth?
Jan 15Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Deliver On Growth Plans?
Oct 02Is Galmed Pharmaceuticals (NASDAQ:GLMD) In A Good Position To Invest In Growth?
May 20Galmed gets greenlight for late-stage Aramchol NASH trial in China
May 03What Type Of Shareholders Own The Most Number of Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) Shares?
Feb 04
We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Can Afford To Drive Business Growth
Dec 06Galmed EPS misses by $0.02
Nov 12Revenue & Expenses Breakdown
How Galmed Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -6 | 4 | 3 |
| 30 Jun 24 | 0 | -6 | 3 | 3 |
| 31 Mar 24 | 0 | -6 | 4 | 3 |
| 31 Dec 23 | 0 | -7 | 4 | 4 |
| 30 Sep 23 | 0 | -8 | 4 | 4 |
| 30 Jun 23 | 0 | -11 | 4 | 8 |
| 31 Mar 23 | 0 | -14 | 4 | 9 |
| 31 Dec 22 | 0 | -18 | 5 | 13 |
| 30 Sep 22 | 0 | -23 | 5 | 18 |
| 30 Jun 22 | 0 | -25 | 5 | 20 |
| 31 Mar 22 | 0 | -30 | 5 | 25 |
| 31 Dec 21 | 0 | -32 | 6 | 27 |
| 30 Sep 21 | 0 | -35 | 6 | 30 |
| 30 Jun 21 | 0 | -34 | 5 | 30 |
| 31 Mar 21 | 0 | -32 | 5 | 28 |
| 31 Dec 20 | 0 | -29 | 4 | 26 |
| 30 Sep 20 | 0 | -27 | 4 | 24 |
| 30 Jun 20 | 0 | -24 | 4 | 22 |
| 31 Mar 20 | 0 | -23 | 4 | 20 |
| 31 Dec 19 | 0 | -20 | 4 | 18 |
| 30 Sep 19 | 0 | -16 | 4 | 14 |
| 30 Jun 19 | 2 | -12 | 4 | 11 |
| 31 Mar 19 | 2 | -11 | 4 | 10 |
| 31 Dec 18 | 2 | -10 | 4 | 8 |
| 30 Sep 18 | 2 | -10 | 5 | 8 |
| 30 Jun 18 | 1 | -12 | 4 | 8 |
| 31 Mar 18 | 1 | -12 | 4 | 9 |
| 31 Dec 17 | 1 | -12 | 4 | 10 |
| 30 Sep 17 | 1 | -13 | 3 | 12 |
| 30 Jun 17 | 1 | -15 | 3 | 13 |
| 31 Mar 17 | 1 | -16 | 3 | 14 |
| 31 Dec 16 | 0 | -17 | 3 | 14 |
| 30 Sep 16 | 0 | -15 | 3 | 13 |
| 30 Jun 16 | 0 | -14 | 3 | 11 |
| 31 Mar 16 | 0 | -12 | 3 | 10 |
| 31 Dec 15 | 0 | -11 | 3 | 8 |
| 30 Sep 15 | 0 | -9 | 4 | 6 |
| 30 Jun 15 | 0 | -10 | 3 | 7 |
| 31 Mar 15 | 0 | -9 | 3 | 7 |
| 31 Dec 14 | 0 | -9 | 2 | 7 |
| 30 Sep 14 | 0 | -22 | 9 | 11 |
| 30 Jun 14 | 0 | -20 | 8 | 9 |
| 31 Mar 14 | 0 | -19 | 8 | 8 |
Quality Earnings: GLMD is currently unprofitable.
Growing Profit Margin: GLMD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: GLMD is unprofitable, but has reduced losses over the past 5 years at a rate of 21.5% per year.
Accelerating Growth: Unable to compare GLMD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GLMD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: GLMD has a negative Return on Equity (-34.3%), as it is currently unprofitable.